Cite

HARVARD Citation

    Fissolo, N. et al. (2021). Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. Neurology. 8 (4), p. . [Online]. 
  
Back to record